emicizumab (Hemlibra) Report issue

Biologics mAb Multi-specific Orphan Drug FDA Approved FDA First in Class Priority Review FDA

Active Ingredient History

NOW
  • Now
Emicizumab is a humanized bispecific antibody for the treatment of haemophilia A, developed by Genentech and Chugai. A Phase I clinical trial found that it was well tolerated by healthy subjects.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: Yes
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1824.9900 - $13560.2300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

ace910 | emicizumab

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue